Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
44
CVKD Quote, Financials, Valuation and Earnings
Last price:
$9.90
Seasonality move
:
23.77%
Day range:
$9.84 - $11.04
52-week range:
$8.12 - $22.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
7.73x
Volume:
38.4K
Avg. volume:
26.2K
1-year change:
-23.86%
Market cap:
$21.1M
Revenue:
--
EPS (TTM):
-$8.01
Analysts' Opinion
-
Consensus RatingCadrenal Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $35.67, Cadrenal Therapeutics, Inc. has an estimated upside of 250.36% from its current price of $10.18.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $30.00 representing 100% downside risk from its current price of $10.18.
Fair Value
-
According to the consensus of 1 analyst, Cadrenal Therapeutics, Inc. has 250.36% upside to fair value with a price target of $35.67 per share.
CVKD vs. S&P 500
-
Over the past 5 trading days, Cadrenal Therapeutics, Inc. has overperformed the S&P 500 by 8.1% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Cadrenal Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cadrenal Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Cadrenal Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Cadrenal Therapeutics, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Cadrenal Therapeutics, Inc. reported earnings per share of -$1.31.
Enterprise value:
17.3M
EV / Invested capital:
6.32x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.13x
EV / Free cash flow:
-1.46x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$6.7K
Return On Assets:
-219.15%
Net Income Margin (TTM):
--
Return On Equity:
-299.72%
Return On Invested Capital:
-299.69%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$2.1K | -$2.1K | -$6.7K | -$400 | -$400 | |
| Operating Income | -$7.4M | -$7.9M | -$14.7M | -$2.5M | -$2.7M | |
| EBITDA | -$7.4M | -$7.9M | -$14.7M | -$2.5M | -$2.7M | |
| Diluted EPS | -$15.56 | -$7.30 | -$8.01 | -$2.18 | -$1.31 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $127.1K | $9.3M | $4.6M | $4M | |
| Total Assets | -- | $545.3K | $9.3M | $4.7M | $4.1M | |
| Current Liabilities | -- | $672.4K | $563.6K | $1.3M | $1.4M | |
| Total Liabilities | -- | $1.7M | $565.8K | $1.3M | $1.4M | |
| Total Equity | -- | -$1.2M | $8.7M | $3.4M | $2.7M | |
| Total Debt | -- | $528.5K | $2.2K | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$3.1M | -$6.3M | -$11.8M | -$2.2M | -$2.4M | |
| Cash From Investing | -$3.3K | -- | -$11.6K | -- | -$1.9K | |
| Cash From Financing | $12.1M | $1.5M | $11.3M | $1.5M | $648.4K | |
| Free Cash Flow | -$3.1M | -$6.3M | -$11.8M | -$2.2M | -$2.4M | |
CVKD
Sector
Market Cap
$21.1M
$28.5M
Price % of 52-Week High
44.45%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-39.77%
-1.33%
1-Year Price Total Return
-23.86%
-20.32%
Beta (5-Year)
--
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$9.51
200-day SMA
Sell
Level
$13.95
Bollinger Bands (100)
Sell
Level
10.88 - 13.76
Chaikin Money Flow
Sell
Level
-1.8M
20-day SMA
Sell
Level
$10.71
Relative Strength Index (RSI14)
Sell
Level
44.67
ADX Line
Buy
Level
27.93
Williams %R
Neutral
Level
-49.7561
50-day SMA
Sell
Level
$12.38
MACD (12, 26)
Sell
Level
-0.83
25-day Aroon Oscillator
Sell
Level
-88
On Balance Volume
Neutral
Level
2.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.4774)
Sell
CA Score
(Annual)
Level (-4.3357)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (9.9454)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.
Stock Forecast FAQ
In the current month, CVKD has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CVKD average analyst price target in the past 3 months is $35.67.
-
Where Will Cadrenal Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cadrenal Therapeutics, Inc. share price will rise to $35.67 per share over the next 12 months.
-
What Do Analysts Say About Cadrenal Therapeutics, Inc.?
Analysts are divided on their view about Cadrenal Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cadrenal Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $30.00.
-
What Is Cadrenal Therapeutics, Inc.'s Price Target?
The price target for Cadrenal Therapeutics, Inc. over the next 1-year time period is forecast to be $35.67 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CVKD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cadrenal Therapeutics, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of CVKD?
You can purchase shares of Cadrenal Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cadrenal Therapeutics, Inc. shares.
-
What Is The Cadrenal Therapeutics, Inc. Share Price Today?
Cadrenal Therapeutics, Inc. was last trading at $9.90 per share. This represents the most recent stock quote for Cadrenal Therapeutics, Inc.. Yesterday, Cadrenal Therapeutics, Inc. closed at $10.18 per share.
-
How To Buy Cadrenal Therapeutics, Inc. Stock Online?
In order to purchase Cadrenal Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get CVKD Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CVKD
Sector
P/E ratio
--
23.75x
PEG ratio
-0.13x
-0.01x
P/B ratio
7.73x
1.83x
Price / LTM sales
--
1.60x
Growth Metrics
CVKD
Sector
Revenue growth
--
4.85%
Earnings growth
39.76%
11.11%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$1.55
-$0.20
Profitability
CVKD
Sector
Profitability FY 2024
-$1.9K
$3.6M
Return on invested capital
-299.69%
-30.98%
Return on assets
-219.15%
-27.62%
Return on equity
-299.72%
-36.69%
Earnings Date
Last Earnings Date
Dec
9
Next Earnings Date
Dec
9
Estimated Next Earnings Date
Mar
10
Balance Sheet
CVKD
Sector
Total cash
$3.9M
$27.2M
Short term investments
--
$25.7M
Total assets
$10.1M
$79.7M
Long term debt
--
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 59.64% over the past day.
Buy
72
KYMR alert for Dec 8
Kymera Therapeutics, Inc. [KYMR] is up 41.67% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 9.18% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
